Human induced pluripotent stem cells shown at the MIRAI EXPO in Kobe, Japan, March 2015. Archive image, not the AMCHEPRY transplant or the cells used in it. Photo: Yuki Ito / Wikimedia Commons, CC BY-SA 4.0. Cropped.
The first patient in a Japanese post-approval study has received a transplant of stem-cell-derived cells intended to improve movement symptoms in Parkinson’s disease, Sumitomo Pharma disclosed Friday.
The transplantation of AMCHEPRY was completed at Kyoto University Hospital in October, according to the company’s October 30 earnings presentation, pages 15 and 16. The disclosure identifies the first patient treated in this post-marketing Phase 4 study, not the first person ever to receive the cell therapy.
The company did not provide a specific procedure date or report this patient’s response in the update. Friday was the disclosure date, not necessarily the day of the operation, and the milestone does not establish a cure or a new efficacy result.
A cell transplant, not another Parkinson’s pill
AMCHEPRY, also called raguneprocel, contains donor-derived cells made from induced pluripotent stem cells, or iPS cells. The resulting cells are dopaminergic neural progenitor cells: precursors that have not yet developed into dopamine-producing neurons, according to Sumitomo’s product description.
Japan granted the product conditional, time-limited approval on March 6 for improving motor symptoms in Parkinson’s patients whose response to existing drug treatments, including levodopa-containing medicines, is inadequate.
That approval predates the latest transplant. Sumitomo said it would conduct a post-marketing clinical study and surveillance to seek full approval within the designated period. The October disclosure is a step in that process, not an announcement of unrestricted approval or U.S. authorization.
A small study before wider treatment
The company’s current schedule calls for approximately one or two patients in fiscal 2026, about 10 in fiscal 2027 and about 10 to 20 in fiscal 2028. Those are planned enrollment and treatment numbers, not a count of patients already treated.
Sumitomo said priority would go to patients enrolled in the Phase 4 study. After study completion, it plans to expand treatment to more sites and a broader patient population.
The immediate development is therefore limited but concrete: a first transplantation has been completed in the Japanese post-approval study, while patient follow-up and the work needed for full approval remain ahead.
JBizNews Desk | JAPAN
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
